Showing results (251-260 of 330) with videos related to

Sort By:
Pageof 33
The Lancet. Oncology|August 19, 2007
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick, Katja Ott, Bernd-Joachim Krause, et al.
Lancet (London, England)|August 24, 2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, et al.
Future Oncology (London, England)|June 11, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summaryKohei Shitara, Manish A Shah, Florian Lordick, et al.
BMC Cancer|May 26, 2019
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupAnna Dorothea Wagner, Heike I Grabsch, Murielle Mauer, et al.
Oncology Research and Treatment|October 22, 2019
Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence AssessmentJonas Kuon, Jeannette Vogt, Anja Mehnert, et al.
The Lancet. Oncology|April 19, 2013
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, et al.
Expert Review of Anticancer Therapy|November 5, 2021
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international facultyMike Nguyen, Eva Segelov, David Goldstein, et al.
British Journal of Cancer|July 3, 2018
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trialAnne Katrin Berger, Stephan Lücke, Ulrich Abel, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 17, 2023
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancerFlorian Lordick, Salah-Eddin Al-Batran, Dirk Arnold, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
Pageof 33